Galecto, Inc. highlighted the successful acquisition of Damora as a key milestone in its ongoing strategic expansion. The integration of Damora and the addition of new senior leadership are expected to strengthen Galecto’s position in the biopharmaceutical sector and accelerate the advancement of its pipeline programs, including anticipated IND submissions for DMR-001 and DMR-002 in 2026. The company emphasized that these developments mark the beginning of a new chapter aimed at delivering transformative therapies for patients with blood cancers.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galecto Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 9623570) on January 12, 2026, and is solely responsible for the information contained therein.